Amalgamated Bank Has $49,000 Stock Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Amalgamated Bank increased its position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 30.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,182 shares of the company’s stock after buying an additional 511 shares during the period. Amalgamated Bank’s holdings in Nurix Therapeutics were worth $49,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Nurix Therapeutics by 31.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,330 shares of the company’s stock valued at $54,000 after acquiring an additional 559 shares in the last quarter. GAMMA Investing LLC lifted its stake in shares of Nurix Therapeutics by 299.8% in the second quarter. GAMMA Investing LLC now owns 4,566 shares of the company’s stock valued at $95,000 after buying an additional 3,424 shares in the last quarter. International Assets Investment Management LLC grew its holdings in shares of Nurix Therapeutics by 1,098.4% during the third quarter. International Assets Investment Management LLC now owns 4,494 shares of the company’s stock valued at $101,000 after buying an additional 4,119 shares during the last quarter. EntryPoint Capital LLC acquired a new stake in shares of Nurix Therapeutics in the 1st quarter worth about $123,000. Finally, ProShare Advisors LLC lifted its position in Nurix Therapeutics by 9.1% in the 1st quarter. ProShare Advisors LLC now owns 11,978 shares of the company’s stock valued at $176,000 after acquiring an additional 998 shares in the last quarter.

Nurix Therapeutics Stock Performance

Shares of NRIX stock opened at $21.79 on Tuesday. The firm has a market capitalization of $1.54 billion, a price-to-earnings ratio of -7.49 and a beta of 2.20. The stock’s 50-day simple moving average is $24.51 and its 200-day simple moving average is $21.34. Nurix Therapeutics, Inc. has a fifty-two week low of $5.65 and a fifty-two week high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX) last posted its earnings results on Friday, October 11th. The company reported ($0.67) EPS for the quarter, hitting the consensus estimate of ($0.67). Nurix Therapeutics had a negative return on equity of 63.39% and a negative net margin of 313.65%. The firm had revenue of $12.59 million for the quarter, compared to analyst estimates of $13.85 million. As a group, equities analysts forecast that Nurix Therapeutics, Inc. will post -2.81 earnings per share for the current year.

Insider Activity at Nurix Therapeutics

In other news, insider Christine Ring sold 9,870 shares of the company’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $25.01, for a total value of $246,848.70. Following the completion of the sale, the insider now directly owns 24,592 shares in the company, valued at $615,045.92. This represents a 28.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Houte Hans Van sold 3,546 shares of the company’s stock in a transaction on Friday, November 1st. The shares were sold at an average price of $24.28, for a total value of $86,096.88. Following the completion of the sale, the chief financial officer now owns 33,724 shares of the company’s stock, valued at approximately $818,818.72. The trade was a 9.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 57,321 shares of company stock valued at $1,414,409. 7.20% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. Jefferies Financial Group started coverage on Nurix Therapeutics in a research note on Friday, October 11th. They set a “buy” rating and a $41.00 price objective on the stock. UBS Group began coverage on shares of Nurix Therapeutics in a research report on Thursday, October 24th. They issued a “buy” rating and a $35.00 price objective for the company. Royal Bank of Canada cut their target price on Nurix Therapeutics from $27.00 to $26.00 and set an “outperform” rating on the stock in a research note on Monday, October 14th. Needham & Company LLC reaffirmed a “buy” rating and set a $29.00 price target on shares of Nurix Therapeutics in a research report on Wednesday, November 6th. Finally, Truist Financial assumed coverage on Nurix Therapeutics in a report on Wednesday, July 31st. They set a “buy” rating and a $36.00 price objective for the company. One equities research analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $29.40.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.